Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578347 | 0.87 | TDP1 (0.51) | TDP1L3MBTL1MAPK1SMN1; SMN2RAB9A | |
| SCHEMBL6954199 | 0.82 | HDAC7 (0.52) | TDP1L3MBTL1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL3359985 | 0.82 | HDAC7 (0.52) | TDP1L3MBTL1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL7898753 | 0.82 | HDAC7 (0.52) | TDP1L3MBTL1SMN1; SMN2RAB9AMAPT | |
| SCHEMBL7215474 | 0.81 | CASP3 (0.50) | TDP1L3MBTL1MAPK1SMN1; SMN2RAB9A | |
| SCHEMBL8527564 | 0.81 | HDAC1 (0.49) | TDP1MAPTTSHRALDH1A1LMNA | |
| SCHEMBL7292349 | 0.80 | HDAC1 (0.48) | TDP1L3MBTL1SMN1; SMN2MAPTTSHR | |
| SCHEMBL442293 | 0.80 | MMP2 (0.44) | SMN1; SMN2RAB9AMAPTTSHRALDH1A1 | |
| SCHEMBL7289974 | 0.80 | HDAC1 (0.48) | TDP1L3MBTL1SMN1; SMN2MAPTTSHR | |
| SCHEMBL7289359 | 0.80 | HDAC1 (0.48) | TDP1L3MBTL1SMN1; SMN2MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940841-B9 | COMPOUNDS COMPRISING A BIOLOGICAL TARGET RECOGNIZING PART, COUPLED TO A SIGNAL PART CAPABLE OF COMPLEXING GALLIUM | GUERBET SA (FR) | 2017-04-19 | — | — | EP | disclosed |
| EP-1940841-B1 | COMPOUNDS COMPRISING A BIOLOGICAL TARGET RECOGNIZING PART, COUPLED TO A SIGNAL PART CAPABLE OF COMPLEXING GALLIUM | GUERBET SA (FR) | 2016-12-07 | — | — | EP | disclosed |
| US-8986650-B2 | Complex folate-NOTA-Ga68 | GUERBET (FR) | 2015-03-24 | — | — | US | disclosed |
| US-8986650-B2 | Complex folate-NOTA-Ga68 | GUERBET (FR) | 2015-03-24 | — | — | US | disclosed |
| US-8926945-B2 | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium | GUERBET (FR) | 2015-01-06 | — | — | US | disclosed |
| US-8926945-B2 | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium | GUERBET (FR) | 2015-01-06 | — | — | US | disclosed |
| US-8926945-B2 | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium | GUERBET (FR) | 2015-01-06 | — | — | US | disclosed |
| EP-1796738-B1 | BICYCLAM CONJUGATE FOR MRI AND SCINTIGRAPHY OF DISEASES ASSOCIATED WITH THE CXCR4 RECEPTOR | GUERBET SA (FR) | 2013-08-07 | — | — | EP | disclosed |
| US-8367039-B2 | Compounds for the diagnosis of diseases associated with VCAM expression | GUERBET (FR) | 2013-02-05 | — | — | US | disclosed |
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | GUERBET (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | GUEREBET (FR) | 2011-04-21 | — | — | US | disclosed |
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | GUEREBET (FR) | 2011-04-21 | — | — | US | disclosed |
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | GUEREBET (FR) | 2011-04-21 | — | — | US | disclosed |
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | GUERBET (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20090202435-A1 | Diagnostic compounds for targeting a chemokine receptors | GUERBET (FR) | 2009-08-13 | — | — | US | disclosed |
| EP-1796738-A2 | DIAGNOSTIC COMPOUNDS FOR TARGETING A CHEMOKINE RECEPTOR | GUERBET (FR) | 2007-06-20 | — | — | EP | disclosed |
| US-20070098643-A1 | Oligomers of gadolinium chelates, their applicationascontrast products in magnetic resonance imaging and their synthesis intermediates | GUERBET (FR) | 2007-05-03 | — | — | US | disclosed |
| US-20070098643-A1 | Oligomers of gadolinium chelates, their applicationascontrast products in magnetic resonance imaging and their synthesis intermediates | GUERBET (FR) | 2007-05-03 | — | — | US | disclosed |
| WO-2007042504-A2 | COMPOUNDS COMPRISING A BIOLOGICAL TARGET RECOGNIZING PART, COUPLED TO A SIGNAL PART CAPABLE OF COMPLEXING GALLIUM | GUERBET (FR) | 2007-04-19 | — | — | WO | disclosed |
| WO-2006032704-A2 | DIAGNOSTIC COMPOUNDS FOR TARGETING A CHEMOKINE RECEPTOR | GUERBET (FR) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092806-A1 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium | KLK3, IGF1R, GIPR | TDP1 4424/4885L3MBTL1 3039/4885MAPK1 2617/4885 |
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | TPX2, VIP, BAX | TDP1 2101/4885L3MBTL1 103/4885MAPK1 404/4885 |
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | FOLR1, FOLR2, DHFR | TDP1 4018/4885L3MBTL1 4080/4885MAPK1 4131/4885 |
| US-20070098643-A1 | Oligomers of gadolinium chelates, their applicationascontrast products in magnetic resonance imaging and their synthesis intermediates | MGAT2, MGAT1, MGAT3 | TDP1 3012/4885L3MBTL1 452/4885MAPK1 2817/4885 |
| US-20090202435-A1 | Diagnostic compounds for targeting a chemokine receptors | CCL2, ACKR3, CCR5 | TDP1 4553/4885L3MBTL1 4179/4885MAPK1 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.